BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

 
Anti-microbial peptide SR-0379 stimulates human endothelial progenitor cell-mediated repair of peripheral artery diseases
Tae Wook Lee1, Soon Chul Heo1, Yang Woo Kwon1, Gyu Tae Park1, Jung Won Yoon1, Seung Chul Kim2, Il Ho Jang3, Jae Ho Kim1,4,*
1Department of Physiology and 2Departments of Obstetrics and Gynecology, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea,
3Department of Oral Biochemistry and Molecular Biology, Pusan National University School of Dentistry, Yangsan 50612, Gyeongsangnam-do, Republic of Korea,
4Research Institute of Convergence Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50612, Gyeongsangnam-do, Republic of Korea
Abstract
Ischemia is a major plague of modern life. In the search for peptide drug candidates for curing ischemic disease, we evaluated the effects of an anti-microbial peptide SR-0379 on stem cell-mediated therapy of ischemic diseases. Migration and tube-forming ability of human endothelial progenitor cells (EPCs) were enhanced by SR-0379 treatment in vitro. Intramuscular administration of SR-0379 into murine ischemic hindlimb significantly enhanced blood perfusion and decreased tissue necrosis, and increased the number of blood vessels in ischemic muscle. Moreover, co-administration of SR-0379 together with EPCs more potently stimulated blood perfusion in ischemic hindlimb than intramuscular injection with either SR-0379 or EPC alone. The enhanced blood perfusion was accompanied by a significant increase in the number of CD31- and メ-SMA-positive blood vessels in ischemic hindlimb. These results suggest that SR-0379 is a potential drug candidate for potentiating EPC-mediated therapy of ischemic diseases.
Abstract, Accepted Manuscript(in press) [Submitted on March 10, 2017, Accepted on May 23, 2017]
  Copyright © KSBMB. All rights reserved. / Powered by INFOrang.co., Ltd